DENDRITIC CELLS, RSV AND INFLUENZA INFECTION IN CHILDREN

儿童树突状细胞、RSV 和流感感染

基本信息

  • 批准号:
    6884108
  • 负责人:
  • 金额:
    $ 23.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-15 至 2007-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the principal etiologic agent of bronchiolitis and viral pneumonia in infants and young children worldwide. Influenza viruses also contribute to significant number of hospitalizations among children. While the clinical manifestations are similar, there are remarkable differences in terms of their immune responses. In a simplified comparison, RSV does not induce protective immunity, there is no available vaccine, and it is associated with recurrent wheezing. In contrast, influenza does induce a more effective protective immune response, vaccines are quite effective, and it is not associated with long-term wheezing. This provides an ideal setting for a comparative analysis of the immune responses of children with these two viral infections. Dendritic cells (DCs) constitute a complex system of cells with a unique ability to induce primary immune responses. In addition, emerging evidence indicates that DCs control cytokine production by T cells and regulate the Th1/Th2 balance of the immune responses. Numerous studies have demonstrated the importance of the interaction between viruses and different DCs subsets and how that initial interaction influences the development of the subsequent immune responses. Although to date, not much is known about the interaction between DCs and RSV, our preliminary results suggest a direct participation of DCs in the immune response to RSV infection in children. Our hypothesis is that RSV and influenza virus target DC differentially leading to different immune responses, mostly deleterious in case of RSV and protective in case of influenza. We will begin to address this hypothesis in the following specific aims: 1. To determine how RSV and influenza infection affect human DC subsets in vivo, and 2. To determine how RSV and influenza infection affect human DC subsets in vitro, These studies will permit us to define the nature of the DC subset(s) that constitute the target of RSV and influenza infection in children, and begin to identify the mechanisms implicated in the interaction between these respiratory viruses and DCs.
描述(由申请方提供):呼吸道合胞病毒(RSV)是全球婴幼儿毛细支气管炎和病毒性肺炎的主要病原体。 流感病毒也是导致大量儿童住院的原因之一。 虽然临床表现相似,但在免疫反应方面存在显着差异。 在一个简单的比较中,RSV不诱导保护性免疫,没有可用的疫苗,并且它与反复喘息有关。 相比之下,流感确实会诱导更有效的保护性免疫反应,疫苗相当有效,并且与长期喘息无关。 这为比较分析这两种病毒感染儿童的免疫反应提供了理想的环境。 树突状细胞(Dendritic cells,DC)是一种复杂的细胞系统,具有诱导原发性免疫应答的独特能力。 此外,新出现的证据表明,DC控制T细胞的细胞因子产生并调节免疫应答的Th 1/Th 2平衡。 许多研究已经证明了病毒与不同DC亚群之间相互作用的重要性,以及这种初始相互作用如何影响随后免疫应答的发展。 尽管迄今为止,对DC和RSV之间的相互作用知之甚少,但我们的初步结果表明,DC直接参与了儿童对RSV感染的免疫应答。 我们的假设是RSV和流感病毒不同地靶向DC,导致不同的免疫应答,在RSV的情况下主要是有害的,而在流感的情况下是保护性的。 我们将开始解决这个假设在以下具体目标:1。确定RSV和流感病毒感染如何影响体内人DC亚群,以及2.为了确定RSV和流感病毒感染如何影响体外人DC亚群,这些研究将使我们能够定义构成RSV和流感病毒感染儿童靶点的DC亚群的性质,并开始鉴定这些呼吸道病毒与DC之间相互作用的机制。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Octavio Ramilo其他文献

Octavio Ramilo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Octavio Ramilo', 18)}}的其他基金

Project 1
项目1
  • 批准号:
    10435215
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Project 1
项目1
  • 批准号:
    10599210
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10435212
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10599204
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
High Precision System Analysis of Infant Immune Responses
婴儿免疫反应的高精度系统分析
  • 批准号:
    10267402
  • 财政年份:
    2020
  • 资助金额:
    $ 23.4万
  • 项目类别:
High Precision System Analysis of Infant Immune Responses
婴儿免疫反应的高精度系统分析
  • 批准号:
    10224030
  • 财政年份:
    2017
  • 资助金额:
    $ 23.4万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    7696466
  • 财政年份:
    2009
  • 资助金额:
    $ 23.4万
  • 项目类别:
Diagnosis of Infections in Humans with Microarrays
用微阵列诊断人类感染
  • 批准号:
    7686544
  • 财政年份:
    2008
  • 资助金额:
    $ 23.4万
  • 项目类别:
DENDRITIC CELLS, RSV AND INFLUENZA INFECTION IN CHILDREN
儿童树突状细胞、RSV 和流感感染
  • 批准号:
    6719713
  • 财政年份:
    2004
  • 资助金额:
    $ 23.4万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    8377861
  • 财政年份:
  • 资助金额:
    $ 23.4万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了